Drug Profile
EDP 788
Alternative Names: EDP-788Latest Information Update: 24 Apr 2016
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class Antibacterials; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 24 Apr 2016 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (IV)
- 07 Jan 2015 Enanta Pharmaceuticals completes enrolment in its phase I trial in Healthy volunteers in USA (NCT02255968)
- 01 Oct 2014 Enanta Pharmaceuticals terminates a phase I trial in Healthy volunteers in USA (PO) (NCT02255968)